Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TUB-010

            Therapeutic Area: Oncology Product Name: TUB-010

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Tubulis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership December 02, 2020

            Details:

            WuXi Biologics and WuXi STA will perform scale-up, process development and GMP manufacturing for the ADC product intermediates. The first program from Tubulis’ pipeline the companies will collaborate on is TUB-010.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HG030

            Therapeutic Area: Oncology Product Name: HG030

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Guangzhou Baiyunshan Pharmaceutical Holdings

            Deal Size: Undisclosed Upfront Cash: $5.8 million

            Deal Type: Licensing Agreement November 10, 2020

            Details:

            Baiyunshan will get exclusive rights to develop and market HG030 in mainland China, and will pay HitGen an upfront licensing fee and a series of milestones and royalty of sales as the product progresses through clinical trials and launches in the mainland China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human antibodies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: CMB International

            Deal Size: $142.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing September 24, 2020

            Details:

            Project Integrum aims at developing, and bringing to market novel therapeutic antibody candidates for difficult druggable targets. Biocytogen's Pipeline includes, RenMab-based target knockout mice, customized target humanized mouse models and gene therapy platforms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 7×21 CAR-T cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2020

            Details:

            Study results indicated the 7×21 CAR-T cells significantly outperformed the conventional CAR-T cells in cell proliferation and chemotaxis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TJ-CD4B

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 12, 2020

            Details:

            The pre-clinical validation of TJ-CD4B/ABL111 to be presented at AACR signifies the overall progress of I-Mab’s bispecific antibody portfolio, reflecting Company’s discovery and CMC capabilities to engineer novel molecules with combined target specificities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APG-3526

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            Ascentage Pharma will report six research results involving multiple cancer types in poster presentations during the meeting. Among them, APG-3526, the company's newest drug candidate, will be presented for the first time.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SIRP-alpha antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Alector

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 26, 2020

            Details:

            Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody drug conjugates

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Navrogen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 04, 2020

            Details:

            ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies.